NCT02852824View on ClinicalTrials.gov

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 10, 2016

Primary Completion Date

August 1, 2017

Study Completion Date

August 1, 2017

Conditions
Healthy
Interventions
DRUG

BI 655130 (spesolimab)

DRUG

Placebo

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY